Apollo Hospitals Enterprise Ltd , one of India's leading healthcare providers, has reported robust financial results for the second quarter of fiscal year 2026, demonstrating strong growth across its diverse healthcare segments.

Financial Highlights

The company's consolidated performance for Q2 FY26 shows significant year-over-year improvements:

Segment-wise Performance

Healthcare Services

The Healthcare Services division, which includes hospitals, reported a 9% year-over-year revenue growth to ₹3,169.00 crore. EBITDA for this segment increased by 8% to ₹781.00 crore, maintaining a strong margin of 24.60%.

Apollo Health and Lifestyle Limited (AHLL)

AHLL, which encompasses diagnostics and retail healthcare, saw a robust 17% year-over-year revenue growth, reaching ₹474.00 crore. EBITDA for this segment grew by 21% to ₹50.00 crore.

Apollo HealthCo

The digital healthcare and omni-channel pharmacy platform reported a 17% year-over-year revenue growth to ₹2,661.00 crore. This segment's EBITDA showed significant improvement, reaching ₹110.00 crore compared to ₹52.00 crore in the same quarter last year.

Operational Highlights

• The company maintained an overall hospital occupancy rate of 69%, slightly lower than the 73% reported in the same period last year.
• Apollo HealthCo expanded its offline pharmacy network, adding 186 new stores during the quarter, bringing the total to 6,928 stores.
• The digital platform Apollo 24/7 reported a GMV (Gross Merchandise Value) of ₹723.00 crore, representing a 16% growth over Q2 FY25.

Strategic Developments

Apollo Hospitals continued to focus on technological advancements and expansion:

• Soft-launched Apollo Athenaa, Asia's first dedicated cancer center for women in Delhi.
• Opened a new multi-specialty tertiary care hospital, Royal Mudhol Apollo Hospitals, in Pune.
• Received approval from the Competition Commission of India for the restructuring plan involving group entities, which is expected to unlock shareholder value.

Management Commentary

Dr. Prathap C Reddy, Chairman of Apollo Hospitals Enterprise Ltd, expressed satisfaction with the quarter's performance, highlighting the company's 42-year legacy in healthcare. He emphasized Apollo's commitment to technological innovation, including AI-driven diagnostics and personalized treatment pathways.

Conclusion

Apollo Hospitals' Q2 FY26 results demonstrate the company's strong position in the Indian healthcare sector, with growth across all major segments. The focus on technological advancements and expansion of both physical and digital healthcare services positions Apollo well for continued growth in the evolving healthcare landscape.

Investors and stakeholders may view these results positively, considering the robust financial performance and strategic initiatives undertaken by the company. However, it's important to note that future performance may be subject to various factors including market conditions and regulatory environments.

Apollo Hospitals Enterprise Ltd has announced a scheduled Board of Directors meeting on November 6, 2025, to review and approve the company's unaudited financial results for the second quarter of the fiscal year 2026. This meeting will cover the financial performance for both the three and six months ended September 30, 2025.

Key Details of the Announcement

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading, Apollo Hospitals has implemented a trading window closure. This measure is designed to prevent insider trading and ensure fair market practices.

The company has taken steps to inform relevant stock exchanges about the scheduled board meeting and trading window closure. This proactive communication aligns with the regulatory requirements outlined in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and market participants are advised to take note of these dates, particularly the trading window closure period, to ensure compliance with regulatory guidelines. The financial results, once approved and announced, will provide valuable insights into Apollo Hospitals' performance for the first half of the fiscal year 2026.